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Abstract An expression cassette containing mouse U6 poly-
merase III promoter directing expression of short hairpin
RNA (shRNA) targeting murine microsomal glucose-6-phospha-
tase (G6P) transcript was generated. This construct was pack-
aged into an adenoviral (AdV) backbone and viral stocks gen-
erated. Mice injected intravenously with AdV-G6PshRNA
exhibited a signi¢cant reduction in postprandial glucose levels
and had signi¢cantly elevated steady-state hepatic glycogen
stores. Target gene silencing was con¢rmed by measurements
demonstrating a signi¢cant reduction in both hepatic G6P tran-
script level and phosphohydrolase activity. These ¢ndings pro-
vide evidence that AdV delivery of expressed shRNA can be a
productive tool to explore gene function in vivo.
) 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The RNA interference (RNAi) pathway is an evolutionarily
conserved gene silencing mechanism elicited by double-
stranded RNA [1,2]. There is great current interest in the
application of RNAi as a research tool in studies of gene
function. In mammalian cell lines and mouse model systems,
e⁄cient gene silencing has been achieved by the direct intro-
duction of short interfering RNAs (siRNAs) or via the tran-
scription of short hairpin RNAs (shRNAs) from expression
vectors or viral delivery systems [3^9]. Recent advances using
this technology in vivo include the silencing of reporter and
endogenous genes as well as the generation of transgenic ani-
mals with silencing of gene expression in adult mice [10^16].
However, exploitation of the RNAi pathway to induce
changes in either whole body mammalian physiology or broad
metabolic parameters has not been reported to date.
The liver plays a central role in the homeostatic regulation
of blood glucose. When circulating blood glucose levels de-
cline, the liver can rapidly release glucose to fuel the energy
demands of the body. This response is achieved via two dis-
tinct and well characterized biochemical pathways, gluconeo-
genesis and glycogenolysis. A single enzyme, glucose-6-phos-
phatase (G6P) (GenBank accession number NM_008061), is
responsible for catalyzing the ¢nal step in each of these path-
ways [17,18]. Inhibition of glucose-6-phosphate conversion to
free glucose by either genetic ablation of the G6P gene or
pharmacological inhibition of the G6P catalytic site or trans-
locase functionality results in alterations to multiple metabolic
parameters including the development of hypoglycemia and
an elevation of hepatic glycogen stores [19^25].
In this study, we have employed an adenoviral (AdV) vec-
tor system to deliver expressed shRNA complementary to
G6P to normal mice intravenously. G6P gene silencing in
vivo was con¢rmed by direct measurements of hepatic tran-
script level and encoded enzymatic activity and results in al-
terations to whole animal glucose homeostasis and hepatic
glycogen content. Our ¢ndings provide the ¢rst report of
quantitative physiological alterations achieved by viral deliv-
ery of shRNA in vivo. These results highlight the potential to
use this technology for the study of gene function in the con-
text of whole animal physiology.
2. Materials and methods
2.1. shRNA and green £uorescent protein (GFP) template expression
vector construction
shRNA expression vector, pShuttle-U6, was constructed by replac-
ing the CMV promoter from vector pShuttle (Becton Dickinson) with
a polymerase chain reaction (PCR)-ampli¢ed mouse U6 promoter
fragment from C57BL/6J genomic DNA (primer sequences: 5P-gatcc-
gacgccgccatctcta-3P and 5P-cacaaacaaggcttttctccaa-3P). For generation
of G6PshRNA, a pair of oligonucleotides 55 bp in length (5P-
tttggagtcgtgtcaggcattgttcaagagacaatgcctgacacgactcctttttg-3P) and (5P-
gatccaaaaaggagtcgtgtcaggcattgtctcttgaacaatgcctgacacgactc-3P) were
synthesized, annealed and ligated between the BsaI and BamHI sites
of pShuttle-U6. The expressed hairpin is complementary to nucleo-
tides 550^568 in the mRNA sequence. Generation of the 2 bp mutant
G6PshRNA was as described as above but with the use of a two
nucleotide substitution (large font) in the sequences (5P-tttggaTtcgtgt-
caggcattgttcaagagacaatgcctgacaAgactcctttttg-3P) and (5P-gatccaaaaag-
gagtcTtgtcaggcattgtctcttgaacaatgcctgacaAgactc-3P). For construction
of control GFPshRNA, a pair of oligonucleotides 55 bp (5P-tttgaag-
cagcacgacttcttcttcaagagagaagaagtcgtgctgcttcttttt-3P) and 56 bp (5P-gat-
caaaaagaagcagcacgacttcttctctcttgaagaagaagtcgtgctgcttc-3P) were syn-
thesized, annealed and ligated as described above. For construction
of pG6P-EGFP fusion cDNA, the entire coding sequence of mouse
G6P was ampli¢ed by PCR from mouse liver cDNA. The PCR frag-
ment was digested and ligated into the HindIII and SacII sites of p-
EGFP-N1 (Becton Dickinson).
2.2. Cell culture, transfections and shRNA screening
Mouse L cells, HEK 293 cells and rat H4IIE cells were maintained
in Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% fetal
bovine serum (Clonetics). L cells were seeded at 90% con£uence in 12
well cell culture dishes 24 h prior to transfection. shRNA (1.6 Wg) and
GFP template (0.4 Wg) expression vectors were co-transfected and 48
h later cellular GFP signal was either visualized under a £uorescent
microscope or quanti¢ed using a £uorescent spectrophotometer.
0014-5793 / 03 / $30.00 O 2003 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
doi:10.1016/S0014-5793(03)01499-6
*Corresponding author. Fax: (1)-617-444 1333.
E-mail address: white@mpi.com (D.W. White).
FEBS 28013 22-1-04 Cyaan Magenta Geel Zwart
FEBS 28013 FEBS Letters 558 (2004) 69^73
2.3. Adenovirus packaging and in vitro validation
The shRNA cassettes cloned in the pShuttle-U6 vector was pack-
aged into adenovirus using the Adeno-X viral expression system (Bec-
ton Dickinson). High titer virus (1U1012 pfu/ml) was generated by
large-scale infection and ampli¢cation in HEK 293 cells followed by
puri¢cation using CsCl gradient ultracentrifugation. For in vitro val-
idation, 1U108 pfu of adenovirus were used to infect 1U106 H4IIE
rat hepatoma cells.
2.4. Animal studies
All studies were performed with the approval of the Millennium
Pharmaceuticals Animal Care and Use Committee. Male C57BL/6J
mice (12 weeks of age) were from Jackson Laboratories.
2.5. Adenoviral delivery in vivo
Adenovirus (5U1010 pfu) containing expression cassettes for either
G6P- or GFP-shRNA or phosphate-bu¡ered saline (PBS) vehicle (100
Wl total volume) were injected intravenously into the tail vein of mice.
Serum was collected by tail bleeding 1 day prior to and 3, 5, 7 days
post injection. Livers were collected on the indicated days, snap frozen
in dry ice and stored at 380‡C.
2.6. Real-time quantitative PCR
Total RNA was isolated from liver tissue and 2 Wg was DNase
treated and reverse transcribed. Quantitative gene expression was per-
formed on an ABI Prism 7700 machine (Applied Biosystems). Ap-
proximately 20 ng of cDNA was used for each reaction. Commercially
available mouse 18S RNA cDNA primer and probe was used as an
internal standard. All data analysis was performed as recommended
by the manufacturer. G6P mRNA levels were normalized to those of
the housekeeping gene and are expressed as relative fold di¡erences.
2.7. Liver G6P assay, serum glucose assay and liver glycogen
determination
Liver microsomal fraction was prepared and G6P activity assay
performed as described [26]. Serum glucose levels were measured using
a glucose color reagent (Raichem) according to the manufacturer’s
protocol. Liver glycogen levels were determined by using the amylo-
glucosidase method as described [27].
2.8. Statistics
Where indicated, values are reported as group averages with stan-
dard deviations. All statistical analysis was performed pair-wise using
a standard Student’s two tailed t-test.
3. Results
We generated a mammalian expression cassette containing
the mouse U6 polymerase III promoter driving expression of
shRNA complementary to the transcript encoding mouse and
rat G6P. E⁄cient gene silencing by G6PshRNA was con-
Fig. 1. Generation and testing of expressed microsomal G6P shRNA. A,B: Signi¢cant reduction in £uorescence intensity in mouse 3T3 L cells
co-transfected with a G6P-EGFP chimeric construct and a vector containing mouse U6 polymerase III promoter directing G6PshRNA expres-
sion. A: Fluorescence microscopic images of L cells 48 h post transfection. B: The EGFP signal from A quanti¢ed with a £uorescent spectro-
meter; vector-transfected cell control was set to 100%. C,D: Adenovirus stocks containing the U6 polymerase III promoter driving G6PshRNA
e⁄ciently silences endogenous G6P gene expression. 1U108 pfu of adenovirus were used to infect 1U106 H4IIE cells (multiplicity of infection
of 100). Cells were harvested 96 h after infection. C: Real-time quantitative PCR analysis demonstrates that G6P mRNA is reduced to approx-
imately 40% of control values. D: G6P enzymatic activity is similarly reduced in cell lysates from the H4IIE cells.
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¢rmed by studies in mouse 3T3 L cells that had been co-trans-
fected with a mouse G6P-EGFP fusion cDNA and the U6-
G6PshRNA construct. As shown in Fig. 1A,B, we observed a
dramatic reduction of EGFP £uorescence intensity in cells
that co-expressed the G6PshRNA. Similar results were found
when G6P-EGFP transcript levels were measured by real-time
PCR or protein levels were measured by Western blotting
(data not shown). Mutation of the G6PshRNA hairpin by a
single bp substitution in the G6P complementary sequence
dramatically reduces the gene silencing e¡ect (Fig. 1A,B).
The U6-G6PshRNA expression construct was then inserted
by homologous recombination into an adenovirus backbone
vector and low titer viral stocks were generated. Initial char-
acterization experiments using rat H4IIE cells indicated that
we could generate infectious AdV particles capable of e⁄-
ciently silencing G6P gene expression to approximately 40%
of control values as evidenced by reduction of G6P mRNA
and enzymatic activity (Fig. 1C,D).
Systemic infusion of recombinant adenovirus results in
transgene delivery predominantly to hepatic tissue [28]. High
titer AdV stocks were therefore generated and experiments
performed to determine whether virally delivered shRNA
could silence hepatic G6P gene expression in vivo. Groups
of C57BL/6J mice were intravenously injected with vehicle,
AdV-G6PshRNA or AdV-GFPshRNA control. We observed
that circulating levels of serum glucose were unchanged in the
three groups of mice at both 24 h and 72 h post infection.
However, on day 5 we detected a dramatic and signi¢cant
reduction in the postprandial serum glucose levels in the
AdV-G6PshRNA-injected animals (148 mg/dl) compared to
the vehicle (167 mg/dl) and control (182 mg/dl) groups (Fig.
2A). In addition to the impact on circulating postprandial
glucose on day 5, mice infected with AdV-G6PshRNA also
exhibited a signi¢cant increase in steady-state hepatic glyco-
gen levels (67.4 mg/g) versus the vehicle (44.1 mg/g) and con-
trol (49.1 mg/g) groups (Fig. 2B). These phenotypic altera-
tions were independent of changes in food intake (data not
shown) and are consistent with a model whereby a reduction
in liver G6P activity gives rise to alterations in glucose homeo-
stasis.
In order to meet energy demands, the mammalian liver can
modulate circulating glucose levels via either an increased rate
of gluconeogenesis or the breakdown of stored liver glycogen.
Hepatic G6P catalyzes the ¢nal and essential enzymatic step
in either process [17^19]. Consequently, to determine whether
the AdV-G6PshRNA-infected mice would respond normally
to lowered circulating glucose by increasing output from the
liver, mice were metabolically challenged by an overnight
(16 h) fast on day 7 post injection with AdV-G6PshRNA.
Livers were then isolated and glycogen levels were quanti¢ed.
Fig. 2. AdV-G6PshRNA decreases postprandial serum glucose and liver glycogen levels in mice. A,B: Male C57BL/6J mice were intravenously
injected with 100 Wl PBS (vehicle) or 5U1010 pfu. AdV-G6PshRNA or AdV-GFPshRNA (control). A: Serum glucose levels were measured
5 days post injection at 10.00 h. Glucose levels for each animal are shown, with each symbol representing one individual animal; group aver-
ages are illustrated with the hatched line (n=9/group). Mice that received AdV-G6PshRNA had signi¢cantly reduced serum glucose levels (148
mg/dl) compared to the vehicle (170 mg/dl) and control (c-shRNA; 182 mg/dl) groups (*P6 0.05, **P6 0.005). B: Livers were harvested and
glycogen levels were measured. Each symbol represents the glycogen value of one individual mouse; group averages are illustrated with the
hatched line (n=8/group). Groups infected with AdV-G6PshRNA have signi¢cantly higher glycogen levels (67.4 mg/g) compared to the vehicle
(44.1 mg/g) and control groups (49.1 mg/g) (*P6 0.01, **P6 0.05).
Fig. 3. Retained liver glycogen stores are elevated in AdV-
G6PshRNA-treated mice following overnight fast. Male C57BL/6J
mice were intravenously injected with 100 Wl PBS (vehicle) or
5U1010 pfu AdV-G6PshRNA or AdV-GFPshRNA (control). Mice
were fasted overnight on day 7 following virus injection. Livers
were harvested and glycogen levels measured. Each symbol repre-
sents the glycogen value of one individual mouse; group averages
are illustrated with the hatched line (n=9/group). Groups treated
with AdV-GFPshRNA retain signi¢cantly higher glycogen levels
(8.38 mg/g) compared to the vehicle (3.36 mg/g) and control
(c-shRNA; 3.55 mg/g) groups (*P6 0.05, **P6 0.005).
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We detected a signi¢cant increase in retained hepatic glycogen
stores in the fasted AdV-G6PshRNA-infected mice (8.38 mg/
g) compared to the vehicle (3.36 mg/g) and control (3.55 mg/g)
groups (Fig. 3).
To con¢rm directly that we had successfully silenced liver
G6P gene expression in the AdV-G6PshRNA-injected mice,
we assessed both hepatic G6P transcript levels and the en-
coded G6P enzymatic activity on day 8 post infection. We
measured a signi¢cant reduction of both G6P mRNA (ap-
proximately 35%) and the encoded phosphohydrolase activity
(approximately 40%) in the AdV-G6PshRNA groups (Fig.
4A,B). Thus, our data provide clear evidence that we have
e⁄ciently silenced hepatic G6P gene expression that has re-
sulted in physiological changes manifested as alterations to
whole body glucose homeostasis and the mechanism of fast-
ing-induced glycogenolysis.
4. Discussion
Exploitation of the RNAi pathway has recently emerged as
a productive means to assess mammalian gene function both
in vitro and in vivo (reviewed in [1,2]). E⁄cient gene silencing
in mice has been successfully achieved by the direct hydro-
dynamic delivery of siRNAs or via the transcription of
shRNAs from expression vectors or viral delivery systems
[10^16]. Although exciting progress in application of this tech-
nology has been reported, the use of virally delivered shRNA
to induce changes in either whole body mammalian physio-
logical or metabolic parameters has not been reported to date.
In this study, we have used adenovirus to deliver shRNA
complementary to G6P to livers of wild type mice. Successful
silencing of hepatic gene expression by G6PshRNA was con-
¢rmed by direct measurements of both G6P mRNA and the
encoded enzymatic activity. We measured an approximate 30^
40% reduction in hepatic G6P transcript and enzymatic activ-
ity levels on day 8 post infection (Fig. 4A,B). Interestingly,
although G6P heterozygous knock-out mice have a 50% re-
duction in measured liver G6P enzymatic activity, these mice
exhibit no changes in circulating postprandial glucose levels or
glycogen stores compared to wild type litter mates [21]. The
discrepancy in observed phenotypes could be due to compen-
satory changes in the heterozygous knock-out mice. Alterna-
tively, these results could imply that shRNA-induced G6P
silencing may have potentially exceeded 50% e⁄ciency during
time points of this study when serum glucose levels were sig-
ni¢cantly decreased following AdV-shRNA infection (for ex-
ample on day 5 post infection). However, measured e¡ects on
circulating serum glucose levels under these conditions would
not become apparent until turnover of existing hepatic G6P
enzymatic activity was substantial. Clearly, additional exper-
imentation will be required to de¢ne the peak, duration and
viral load for optimal AdV-mediated G6PshRNA gene silenc-
ing.
Hepatic G6P gene silencing results in a signi¢cant reduction
of normal circulating glucose levels and a signi¢cant increase
in liver glycogen stores (Fig. 2A,B). In addition, infection with
AdV-G6PshRNA results in alterations to normal hepatic gly-
cogenolysis in response to overnight fast (Fig. 3). Our ¢ndings
are in agreement with previous observations describing the use
of synthetic small molecule inhibitors of G6P function (cata-
lytic site or translocase activity) to lower circulating blood
glucose concentrations in rats and mice [22^26]. Moreover,
these ¢ndings agree with the pathophysiology of glycogen
storage disease type 1a (GSD-1a) in humans, a homozygous
recessive disorder resulting from loss of G6P activity [20].
Patients with GSD-1a exhibit severe hypoglycemia and in-
creased glycogen storage in the liver. Engineered G6P
knock-out mice closely mimic the pathophysiology of human
GSD-1a patients [19]. However, at present we cannot exclude
the possibility that the observed e¡ects of G6PshRNA on
hepatic glucose homeostasis could be due in part to
shRNA-induced non-speci¢c responses as previously reported
by Bridge and colleagues [29].
In summary, our study provides the ¢rst example of quan-
titative physiological and metabolic perturbations achieved by
viral delivery of expressed shRNA in vivo and clearly high-
Fig. 4. AdV-G6PshRNA treatment e⁄ciently silences hepatic microsomal G6P expression in mice. A,B: Male C57BL/6J mice were intrave-
nously injected with 100 Wl PBS (vehicle) or 5U1010 pfu of AdV-G6PshRNA or AdV-GFPshRNA (control). Livers were collected 8 days post
virus infection and both mRNA levels and hepatic G6P enzyme activity were evaluated. Each dot represents the glycogen value of one individ-
ual mouse; group averages are illustrated with the hatched line (n=9/group). Infection with AdV-G6PshRNA results in a signi¢cant reduction
in both (A) G6P transcript level and (B) phosphohydrolase activity compared to the vehicle and control (c-shRNA) groups (*P6 0.05,
**P6 0.005, #P6 0.06).
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lights the potential use of this technology for the comprehen-
sive study of gene function in the context of whole animal
physiology. Although the use of adenovirus to deliver shRNA
to the liver can induce a strong immune response via the
interferon pathway, we believe this mechanism of acute gene
silencing may provide a viable alternative to the use of hydro-
dynamic injection to deliver siRNA [15,16]. This is due in part
to the large volume requirements for hydrodynamic injections,
the consequential impact on whole body physiology and the
stability and degradation kinetics of siRNA compared to
shRNA. However, additional comparative studies between
these two methodologies will be necessary to gauge both phys-
iological impact, cellular transduction e⁄ciencies and the
length and magnitude of gene suppression that can be
achieved in vivo.
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